You have free access to this content

Cancer

Cover image for Cancer

1 October 2009

Volume 115, Issue 19

Pages 4431–4644

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
      New law will place important restrictions on tobacco (page 4433)

      Carrie Printz

      Version of Record online: 17 SEP 2009 | DOI: 10.1002/cncr.24654

  2. Review Article

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    1. You have free access to this content
      Pulmonary neuroendocrine/carcinoid tumors : A review article (pages 4434–4441)

      Erin M. Bertino, Patricia D. Confer, Jorge E. Colonna, Patrick Ross and Gregory A. Otterson

      Version of Record online: 26 JUN 2009 | DOI: 10.1002/cncr.24498

      • original image
      • original image

      This article reviewed the recent literature regarding pulmonary carcinoid/well-differentiated neuroendocrine tumors. Clinical, pathologic, and radiographic evaluations were discussed as well as treatment strategies.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism : A Danish population-based cohort study (pages 4442–4449)

      Rohini K. Hernandez, Henrik Toft Sørensen, Lars Pedersen, Jacob Jacobsen and Timothy L. Lash

      Version of Record online: 30 JUN 2009 | DOI: 10.1002/cncr.24508

      • original image

      Tamoxifen therapy increases the risk of deep venous thrombosis and pulmonary embolism (DVT/PE), but to the authors' knowledge it is not yet known whether the risk changes with the amount of time elapsed since the initial tamoxifen prescription. The findings of the current study suggested that the first 2 years after the initiation of tamoxifen therapy were possibly the most crucial time for monitoring DVT/PE risk, particularly in older women.

    2. Gastrointestinal Disease
      You have free access to this content
      Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy (pages 4450–4458)

      Fadi Braiteh, Arlene M. Correa, Wayne L. Hofstetter, David C. Rice, Ara A. Vaporciyan, Garrett L. Walsh, Jack A. Roth, Reza J. Mehran, Stephen G. Swisher and Jaffer A. Ajani

      Version of Record online: 26 JUN 2009 | DOI: 10.1002/cncr.24488

      • original image
      • original image
      • original image
      • original image
      • original image

      In this analysis of 600 hundred consecutive patients with esophageal cancer who underwent surgery, patients aged ≤60 years achieved the best overall survival and experienced fewer surgical complications compared with older patients, and patients aged >70 years consistently had shorter overall survival and higher rates of surgical complications. The results indicated that age is an important variable in the selection of patients for esophageal cancer surgery.

    3. You have free access to this content
      Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer (pages 4459–4469)

      Shuiping Tu, Raymond Wai-Yin Sun, Marie C. M. Lin, Jian Tao Cui, Bing Zou, Qing Gu, Hsiang-Fu Kung, Chi-Ming Che and Benjamin C. Y. Wong

      Version of Record online: 1 JUL 2009 | DOI: 10.1002/cncr.24514

      • original image
      • original image
      • original image
      • original image
      • original image

      The gold (III) complex gold 1a had antitumor effects both in vitro and in vivo in human colon cancer. The cytotoxic effect acted mainly through the induction of apoptosis and through cell cycle arrest.

    4. Genitourinary Disease
      You have free access to this content
      Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy : Results from CaPSURE (pages 4470–4476)

      Robert Abouassaly, Alan Paciorek, Charles J. Ryan, Peter R. Carroll and Eric A. Klein

      Version of Record online: 27 JUL 2009 | DOI: 10.1002/cncr.24526

      • original image

      This study identified clinical risk factors for disease progression in prostate cancer patients treated with androgen deprivation therapy (ADT). Risk category, percentage of positive biopsies, age, and prostate–specific antigen velocity while receiving ADT were found to be significantly associated with the development of metastatic disease after ADT.

    5. You have free access to this content
      Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? (pages 4477–4487)

      James W. Denham, Allison Steigler, Chantelle Wilcox, David S. Lamb, David Joseph, Chris Atkinson, Keen-Hun Tai, Nigel A. Spry, Paul S. Gleeson and Catherine D'Este

      Version of Record online: 18 AUG 2009 | DOI: 10.1002/cncr.24484

      • original image
      • original image
      • original image
      • original image

      When biochemical recurrence occurs, prognostic factors for survival change. Low initial prostate‒specific antigen (PSA) level, short time to biochemical recurrence, and rapid PSA doubling time take over at this point, providing reasons why initial PSA and biochemical recurrence alone predict prostate cancer–specific survival unsatisfactorily.

    6. You have free access to this content
      Wnt antagonist gene polymorphisms and renal cancer (pages 4488–4503)

      Hiroshi Hirata, Yuji Hinoda, Koichi Nakajima, Nobuyuki Kikuno, Soichiro Yamamura, Kazumori Kawakami, Yutaka Suehiro, Z. Laura Tabatabai, Nobuhisa Ishii and Rajvir Dahiya

      Version of Record online: 26 JUN 2009 | DOI: 10.1002/cncr.24491

      • original image
      • original image
      • original image

      The authors documented findings that Dickkopf 3 (DKK3) polymorphisms were associated with renal cell carcinoma (RCC) and that the DKK2 single nucleotide polymorphism (SNP) (SNP reference number 17037102) may be a predictor of survival in patients with RCC after they undergo radical nephrectomy.

    7. Head and Neck Disease
      You have free access to this content
      Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : A phase 2 trial of the Eastern Cooperative Oncology Group (pages 4504–4513)

      Athanassios Argiris, Ashley Buchanan, Bruce Brockstein, Jill Kolesar, Musie Ghebremichael, Michael Pins, Kristine Hahn, Rita Axelrod and Arlene Forastiere

      Version of Record online: 24 JUL 2009 | DOI: 10.1002/cncr.24528

      • original image

      The combination of docetaxel and irinotecan was evaluated in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Although toxicities were acceptable, treatment efficacy does not seem to be superior to other chemotherapy regimens for this disease.

    8. You have free access to this content
      Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer (pages 4514–4523)

      Robert Haddad, Stephen Sonis, Marshall Posner, Lori Wirth, Rosemary Costello, Patricia Braschayko, Aaron Allen, Anand Mahadevan, Jayme Flynn, Elaine Burke, Yi Li and Roy B. Tishler

      Version of Record online: 24 JUL 2009 | DOI: 10.1002/cncr.24525

      • original image
      • original image
      • original image

      Patients with locally advanced head and neck cancer are frequently treated with concurrent chemoradiotherapy. Recent meta-analyses have confirmed the advantage of concurrent chemoradiotherapy in patients with newly diagnosed squamous cell carcinoma of the head and neck when compared with the use of radiotherapy alone. In the current study, concurrent chemoradiotherapy with an accelerated concomitant boost and carboplatin/paclitaxel was found to be highly active in patients with locally advanced head and neck cancer.

    9. Hematologic Malignancies
      You have free access to this content
      The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes (pages 4524–4532)

      Ulrike Bacher, Torsten Haferlach, Wolfgang Kern, Tamara Weiss, Susanne Schnittger and Claudia Haferlach

      Version of Record online: 30 JUN 2009 | DOI: 10.1002/cncr.24501

      • original image

      This report outlines the power of a combined diagnostic approach for suspected initial cases of myelodysplastic syndromes, including immunophenotyping, cytogenetics, and molecular genetics with selected markers in addition to cytomorphology.

    10. You have free access to this content
      A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia (pages 4533–4539)

      Nitin Jain, William Wierda, Alessandra Ferrajoli, Franklin Wong, Susan Lerner, Michael Keating and Susan O'Brien

      Version of Record online: 27 JUL 2009 | DOI: 10.1002/cncr.24522

      Use of radioimmunotherapy (90Y ibritumomab) in patients with chronic lymphocytic leukemia with <25% bone marrow involvement leads to significant and prolonged myelosuppression with limited clinical efficacy.

  4. Original Article

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    1. Disease Site

      Hematologic Malignancies
      You have free access to this content
      Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma : A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA) (pages 4540–4546)

      Vincent Ribrag, Christian Gisselbrecht, Corinne Haioun, Gilles Salles, Jean-Baptiste Golfier, Marjan Ertault, Christophe Ferme, Josette Briere, Pauline Brice and Nicolas Mounier

      Version of Record online: 10 JUL 2009 | DOI: 10.1002/cncr.24518

      • original image
      • original image
      • original image

      The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma. R-CHOP with bortezomib was an effective regimen and produced an 84% complete response rate, although bortezomib had the potential for dose-limiting neurotoxicity.

  5. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    1. Disease Site

      Hematologic Malignancies
      You have free access to this content
      A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy (pages 4547–4553)

      Alessandra Tucci, Samantha Ferrari, Chiara Bottelli, Erika Borlenghi, Monica Drera and Giuseppe Rossi

      Version of Record online: 26 JUN 2009 | DOI: 10.1002/cncr.24490

      • original image
      • original image
      • original image

      By applying a comprehensive geriatric assessment (CGA) to elderly patients with diffuse large cell lymphoma (DLCL) independently from treatment given, the authors identified a cohort of “fit” patients who could tolerate an anthracycline-based treatment and achieve an outcome similar to that of younger patients affected by DLCL. Patients classified as “unfit” according to CGA had a poorer outcome, despite receiving intensive treatment with curative intent or palliation only.

    2. Hepatobiliary Disease
      You have free access to this content
      p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection (pages 4554–4563)

      Xiao-Min Wang, Lian-Yue Yang, Lei Guo, Chun Fan and Fan Wu

      Version of Record online: 23 JUN 2009 | DOI: 10.1002/cncr.24494

      • original image
      • original image
      • original image

      To the authors' knowledge, this is the first report of increased p53-induced RING-H2 protein (PIRH2) expression in patients with hepatocellular carcinoma (HCC). The study also demonstrated that increased expression of PIRH2 correlates with poor survival in patients with HCC, indicating that PIRH2 may be a novel prognostic marker for HCC.

    3. You have free access to this content
      Biliary intraepithelial neoplasia in patients without chronic biliary disease : Analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases (pages 4564–4575)

      Tsung-Teh Wu, Michael Levy, Arlene M. Correa, Charles B. Rosen and Susan C. Abraham

      Version of Record online: 10 AUG 2009 | DOI: 10.1002/cncr.24471

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Explanted livers from patients with alcoholic cirrhosis and hepatitis C cirrhosis had higher rates of biliary intraepithelial neoplasia (BilIN), higher grades of BilIN, and more extensive BilIN as compared with noncirrhotic controls. These findings add morphologic support for the epidemiologic association between intrahepatic cholangiocarcinoma, alcoholic hepatitis, and hepatitis C infection.

    4. You have free access to this content
      Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma (pages 4576–4585)

      Michelle Z. Xu, Tzy-Jyun Yao, Nikki P. Y. Lee, Irene O. L. Ng, Yuk-Tat Chan, Lars Zender, Scott W. Lowe, Ronnie T. P. Poon and John M. Luk

      Version of Record online: 23 JUN 2009 | DOI: 10.1002/cncr.24495

      • original image
      • original image
      • original image

      Yes-associated protein (YAP) is overexpressed in hepatocellular carcinoma, with poor prognostic outcomes, and is clinically correlated with poor tumor differentiation grade and high serum α-fetoprotein level. The authors found that YAP is highly associated with aggressive liver cancer, is a new biomarker for this disease, and is a potential therapeutic target.

    5. Discipline

      Diagnostic Imaging
      You have free access to this content
      The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer (pages 4586–4594)

      Johnny Kao, Ha Linh Vu, Eric M. Genden, Bharat Mocherla, Eunice E. Park, Stuart Packer, Peter M. Som and Lale Kostakoglu

      Version of Record online: 19 JUN 2009 | DOI: 10.1002/cncr.24493

      • original image
      • original image
      • original image

      A total of 240 positron emission tomography/computed tomography (PET/CT) scans were obtained in 80 patients with head and neck cancer who were treated with radiotherapy from July, 2005 through August, 2007. Although follow-up PET/CT is associated with a high false-positive rate in the irradiated head and neck, PET/CT is highly sensitive in detecting recurrent disease and negative scans are accurate and provide significant prognostic value.

    6. Disparities Research
      You have free access to this content
      Treatment and outcomes of gastric cancer among United States-born and foreign-born Asians and Pacific Islanders (pages 4595–4605)

      Stacey A. DaCosta Byfield, Craig C. Earle, John Z. Ayanian and Ellen P. McCarthy

      Version of Record online: 22 JUL 2009 | DOI: 10.1002/cncr.24487

      • original image
      • original image
      • original image

      The authors found that Asian and Pacific Islander (API) gastric cancer patients in the United States are more likely to receive surgery and adequate lymph node assessment compared with non-Hispanic white patients. Foreign-born, but not US-born API patients were also found to experience significantly more favorable survival outcomes than non-Hispanic white patients; this remained significant even after adjusting for tumor characteristics and treatment.

    7. You have free access to this content
      Cancer treatment adherence among low-income women with breast or gynecologic cancer : A randomized controlled trial of patient navigation (pages 4606–4615)

      Kathleen Ell, Betsy Vourlekis, Bin Xie, Frances R. Nedjat-Haiem, Pey-Jiuan Lee, Laila Muderspach, Christy Russell and Lawrence A. Palinkas

      Version of Record online: 23 JUN 2009 | DOI: 10.1002/cncr.24500

      • original image

      The results of this randomized, controlled trial indicated that a treatment funding program, routine efforts to ensure that eligible patients received the funding, and either telephone-delivered navigational information and reminders or written informational materials in Spanish, if preferred, had the potential to facilitate cancer treatment adherence among underserved, low-income Hispanic women in safety-net programs.

    8. Outcomes Research
      You have free access to this content
      Conditional relative survival of cancer patients and conditional probability of death : A French National Database analysis (pages 4616–4624)

      Anne-Marie Bouvier, Laurent Remontet, Guy Hédelin, Guy Launoy, Valérie Jooste, Pascale Grosclaude, Aurélien Belot, Brigitte Lacour, Jacques Estève, Nadine Bossard and Jean Faivre

      Version of Record online: 30 JUN 2009 | DOI: 10.1002/cncr.24489

      • original image

      Data from the French Network of Cancer Registries from 205,562 patients aged <75 years who were diagnosed with cancer between 1989 and 1997 indicated that age did not influence the long-term conditional probabilities of death in the same manner for cancers of the colon or rectum, lung, breast, and prostate. The results from this survival analysis expand current knowledge about these differences in survival.

    9. Psychosocial Oncology
      You have free access to this content
      Mental status changes after hematopoietic stem cell transplantation (pages 4625–4635)

      Grace Chang, Mary-Ellen Meadows, E. John Orav and Joseph H. Antin

      Version of Record online: 23 JUN 2009 | DOI: 10.1002/cncr.24496

      • original image
      • original image

      The overall pattern from measures of neurocognitive function indicated that there were improvements over 18 months in patients who had chronic myelogenous leukemia or myelodysplastic syndrome. When mental status side effects were considered, hematopoietic stem cell transplantation recipients compared favorably with patients who received other treatment.

    10. You have free access to this content
      Complications of radiotherapy in laryngopharyngeal cancer : Effects of a prospective smoking cessation program (pages 4636–4644)

      Jose P. Zevallos, Michael J. Mallen, Cho Y. Lam, Maher Karam-Hage, Jan Blalock, David W. Wetter, Adam S. Garden, Erich M. Sturgis and Paul M. Cinciripini

      Version of Record online: 30 JUN 2009 | DOI: 10.1002/cncr.24499

      Radiotherapy for laryngopharyngeal cancer resulted in significant acute and long-term complications. This prospective study demonstrated that patients who successfully quit smoking before they started treatment had significantly fewer complications.

SEARCH

SEARCH BY CITATION